Reducing Recurrence of Clostridium difficile Infection with Bezlotoxumab (Zinplava)

 

Compound: human monoclonal IgG1/kappa antibody

Target: C. difficile toxin B

 

Dose: 10 mg per kg body weight

Dosage form (concentration): 25 mg/mL in single dose vial (1,000 mg in 40 mL)

Administration: intravenous infusion over 60 minutes

Concentration for infusion (in 0.9% sodium chloride or 5% dextrose): 1-10 mg/mL (dilution factor 2.5 to 25 fold)

Elimination half-life: about 19 days

 

Indications and usage:

(1) The patient must be >= 18 years of age.

(2) The patient has or is at high risk for recurrence of Clostridium difficile infection.

(3) The patient is concurrently receiving appropriate antibiotic therapy against Clostridium difficile.

 

Limitations:

(1) cost: less expensive alternatives may exist